4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline
- CAS No.183322-18-1
- GradeIndustrial / Pharmaceutical
- Availability● In Stock
A high-purity pharmaceutical intermediate crucial for Erlotinib synthesis. Available in bulk with full quality documentation.
Request Bulk PricingProduct Technical Details
Product Overview
4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline is a specialized organic compound serving as a critical building block in the pharmaceutical industry. Primarily recognized for its role in the synthesis of Erlotinib, a potent tyrosine kinase inhibitor used in oncology treatments, this intermediate demands precise manufacturing standards. Our facility produces this chemical under strict quality control protocols to ensure consistency and reliability for downstream API production.
The molecular structure features a quinazoline core substituted with chloro and methoxyethoxy groups, providing the necessary reactivity for subsequent coupling reactions. As a key precursor, the purity and physical stability of this material directly impact the yield and quality of the final therapeutic agent. We understand the critical nature of supply chain continuity for pharmaceutical manufacturers and maintain robust inventory levels to meet global demand.
Technical Specifications
Quality assurance is paramount in the production of pharmaceutical intermediates. Each batch undergoes rigorous analytical testing using advanced instrumentation such as HPLC, NMR, and Mass Spectrometry. The following table outlines the standard specifications for our commercial grade material:
| Parameter | Specification |
|---|---|
| Chemical Name | 4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline |
| CAS Number | 183322-18-1 |
| Molecular Formula | C14H17ClN2O4 |
| Molecular Weight | 312.75 g/mol |
| Appearance | White powder |
| Purity | ≥99.0% |
| Melting Point | 106-108°C |
| Density | 1.257 g/cm3 |
Industrial Applications
This compound is predominantly utilized in the manufacturing of Erlotinib hydrochloride, an epidermal growth factor receptor (EGFR) inhibitor. The high purity level ensures minimal impurity carryover into the final API, which is essential for regulatory compliance in major markets including the US, Europe, and Asia. Beyond Erlotinib, this quinazoline derivative may serve as a versatile scaffold for developing novel kinase inhibitors targeting various therapeutic areas.
- Essential intermediate for oncology drug synthesis
- Compatible with standard nucleophilic substitution reactions
- Supports scale-up from laboratory to commercial production
- Ensures high yield in downstream coupling steps
Quality Assurance and Packaging
We adhere to international safety and quality standards throughout the manufacturing process. Every shipment is accompanied by a Certificate of Analysis (COA) detailing batch-specific test results. The product is packaged in secure 25 kg drums to maintain integrity during transit, though custom packaging solutions are available upon request to suit specific logistical requirements.
Proper storage is essential to maintain chemical stability. The material should be kept in a cool, ventilated area away from direct sunlight and moisture. Our logistics team ensures safe handling and timely delivery to facilitate uninterrupted production schedules for our partners. For technical inquiries or bulk pricing requests, our sales team is ready to provide comprehensive support and documentation.
